GC Biopharma Corp.
Financials
Valuation Metrics
GC Biopharma Corp.'s Market Cap is ₩1.4T. At end of 2025 it was ₩1.9T. Ranked #252 of 2,436 in KR market (top 10%), #193 of 787 on KOSPI (top 25%), #28 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 12%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.40T KRW | KR#252/2,436 Sec#28/234 |
| Revenue | 2.04T KRW | KR#243/2,436 Sec#6/234 |
| Net Income | -39.24B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 2.97T KRW | KR#234/2,436 Sec#8/234 |
| Net Assets | 1.39T KRW | KR#223/2,436 Sec#10/234 |
| Employees | 2,355 | KR#123/2,436 Sec#4/234 |
| Value | ||
| P/B | 1.01x | KR#1,493/2,436 Sec#97/234 |
| P/S | 0.69x | KR#1,139/2,436 Sec#54/234 |
| EV/EBITDA | 30.50x | KR#1,189/2,436 Sec#78/234 |
| FCF Yield | 1.93% | KR#1,076/2,436 Sec#72/234 |
| Profitability | ||
| ROE | -2.81% | KR#1,659/2,436 Sec#119/234 |
| ROA | -1.32% | KR#1,636/2,436 Sec#115/234 |
| Op. Margin | 3.57% | KR#1,130/2,436 Sec#87/234 |
| Revenue Growth | 13.49% | KR#799/2,436 Sec#71/234 |
| Earnings Growth | -32.17% | KR#1,118/2,436 Sec#72/234 |
| Financial Health | ||
| Debt Ratio | 113.09% | KR#507/2,436 Sec#68/234 |
| Total Debt | 862.25B KRW | KR#215/2,436 Sec#7/234 |
| FCF | 27.10B KRW | KR#438/2,436 Sec#25/234 |
| Cash | 40.73B KRW | KR#853/2,436 Sec#55/234 |
| Current Ratio | 1.25x | KR#1,523/2,436 Sec#160/234 |
| Net Debt/EBITDA | 11.27x | KR#1,301/2,436 Sec#93/234 |
| Dividend | ||
| Div. Yield | 1.32% | KR#1,069/2,436 Sec#61/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -11.63% | KR#1,019/2,436 Sec#74/234 |
| 1M Return | -2.28% | KR#1,132/2,436 Sec#109/234 |
| From 52W High | -34.71% | KR#560/2,436 Sec#39/234 |
| 1Y MDD | -37.22% | KR#412/2,436 Sec#31/234 |
| Trading | ||
| Volume | 51,244 shares | KR#1,313/2,436 Sec#129/234 |
| Foreign Own. | 23.30% | KR#176/2,436 Sec#7/234 |
| Per Share | ||
| EPS | -1,189 KRW | KR—/2,436 Sec—/234 |
| BPS | 107,655 KRW | KR#121/2,436 Sec#5/234 |
Company Info
Established in 1969 and headquartered in Yongin-si, Gyeonggi-do, Green Cross is a professional pharmaceutical manufacturer and seller specializing in blood products and vaccine products. Its main businesses include blood products, general products, and vaccine products. The company strengthened its raw plasma procurement capabilities by acquiring US ABO Holdings in 2025 and is entering the global market with ALYGLO's US FDA approval and 2024 launch. Green Cross supplies products to domestic and international markets through its Ochang factory production facilities, aiming to become a global pharmaceutical company focused on key strategic products.